From Discovery to Production of Active Biotherapeutic and Pharmaceutical Ingredients
Jun 19 2018 Read 1121 Times
Kromasil fits across the entire biotherapeutic and pharmaceutical organisations. Typically, researchers carry out method development using Kromasil UHPLC and HPLC columns based on 1.8 - 5 μm particle sizes. Then scientists and engineers in discovery, process and manufacturing departments scale the method up according to their needs using the same Kromasil stationary phases in prepacked columns and bulk ranging from 7 to 25 μm. This Kromasil capability to supply the entire development and production path of an API is unique in the market and shortens the timeline plus minimises costs when producing a drug. With 30 years of experience, Kromasil continues to expand its list of products, provides ready-made columns as well as bulk material for normal phase, reversed phase, chiral, HILIC, SFC and SMB chromatography.
For more information go to www.kromasil.com.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Mobile Affinity Sorbent Chromatography Of Proteins - Integration of MS and UV Data for Peak Tracking in HPLC Method Development - Efficient heat transfer - power...
View all digital editions
Mar 25 2019 Nantes, France
Mar 25 2019 Vienna, Austria
Mar 26 2019 Warsaw, Poland
Mar 26 2019 Paris, France
Mar 26 2019 Suntec City, Singapore